EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort

Alin Abreu Lomba, David Alexander Vernaza Trujillo iD, Carlos Andrés Tafur Monje, Wilfredo Antonio Rivera-Martínez iD, Cesar Augusto Mejía Vélez, Juan S Izquierdo-Condoy iD

Life · 03.07.2026 · 16 (7) · 1114

DOI: 10.3390/life16071114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 03.07.2026. Verfasst von Alin Abreu Lomba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali 760045, Colombia. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Acromegaly is a chronic endocrine disorder caused mainly by GH-secreting pituitary adenomas, leading to excess GH and elevated IGF-1. Although surgery is first-line therapy, many patients require medical treatment, and remission is often not achieved with first-generation somatostatin receptor ligands (SRLs). Pasireotide, a second-generation SRL, offers superior biochemical and tumor control but is associated with hyperglycemia. This study aimed to evaluate real-world outcomes associated with pasireotide treatment in patients with acromegaly inadequately controlled on first-generation SRLs, with IGF-1 normalization as the primary endpoint. Secondary outcomes included GH control, tumor response, and glycemic safety.

Methods

We conducted a historical cohort study of adults with acromegaly treated at Clínica Imbanaco (Cali, Colombia) between 2017 and 2024. Eligible patients had residual tumors and persistently elevated GH and/or IGF-1 levels above the age-adjusted upper limit of normal despite treatment with clinically adequate doses of first-generation SRLs, as well as 12 months of continuous pasireotide treatment and follow-up after pasireotide initiation. Demographic, biochemical, imaging, and glycemic data were collected. Statistical analysis included paired and independent Student’s t-tests, Wilcoxon signed-rank tests, McNemar’s test, and Fisher’s exact test, with significance set at p < 0.05.

Results

Fourteen patients (50% female; mean age 52.1 ± 14.5 years) were included. After 12 months, mean IGF-1 decreased from 2.73 ± 0.73 to 0.99 ± 0.56 × ULN, and 50% achieved IGF-1 normalization. Additionally, 35.7% achieved GH < 1 ng/mL, and 14.3% achieved combined control. Mean tumor diameter decreased by −3.26 mm (95% CI −4.56 to −1.95; p < 0.001). HbA1c increased from 5.56% to 6.05%, while type 2 diabetes mellitus prevalence rose from 14.3% to 35.7%. No patient discontinued pasireotide due to metabolic adverse events.

Conclusions

Pasireotide was associated with favorable biochemical and tumor responses in patients with acromegaly inadequately controlled on first-generation SRLs under real-world conditions. Although treatment was associated with higher HbA1c and increased diabetes incidence, proactive monitoring and early management of hyperglycemia may have supported treatment persistence.

Schlagwörter

Stichwörter der Autor:innen

Individualized endocrine careacromegalymetabolic safetypasireotidereal-world evidence

Autor:innen und Institutionen

  • Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali 760045, Colombia.
  • Endocrinology Department, Clínica Imbanaco, Cali 760042, Colombia.
  • Department of Public Health, Pontificia Universidad Javeriana, Cali 760031, Colombia.
  • Clinical Research Center, Clínica Imbanaco, Cali 760042, Colombia.
  • Endocrinology Department, Clínica Nueva de Cali, Cali 760044, Colombia.
  • Endocrinology Department, IPS Nauru, Cali 760042, Colombia.

ORCID-Profile: David Alexander Vernaza Trujillo, Wilfredo Antonio Rivera-Martínez, Juan S Izquierdo-Condoy

Zitieren

APA

Abreu Lomba, A., Vernaza Trujillo, D. A., Tafur Monje, C. A., Rivera-Martínez, W. A., Mejía Vélez, C. A., & Izquierdo-Condoy, J. S. (2026). Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort. Life, 16(7), 1114. https://doi.org/10.3390/life16071114

Vancouver

Abreu Lomba A, Vernaza Trujillo DA, Tafur Monje CA, Rivera-Martínez WA, Mejía Vélez CA, Izquierdo-Condoy JS. Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort. Life. 2026;16(7):1114. doi:10.3390/life16071114

BibTeX
@article{AbreuLomba2026,
  author = {Abreu Lomba, Alin and Vernaza Trujillo, David Alexander and Tafur Monje, Carlos Andrés and Rivera-Martínez, Wilfredo Antonio and Mejía Vélez, Cesar Augusto and Izquierdo-Condoy, Juan S},
  title = {Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {1114},
  doi = {10.3390/life16071114}
}
Kostenlos starten →